ARTICLE | Politics & Policy
ODAC to discuss accelerated approval requirements
January 7, 2011 1:37 AM UTC
FDA's Oncologic Drugs Advisory Committee will meet on Feb. 8 to discuss ways to improve postmarketing trials required to confirm the benefit of drugs that received accelerated approval. The committee will review the status of postmarketing requirements for six drugs that received accelerated approval. ...